E-LIB Suche - Ergebnisse für: Borsi, Andras

1

Burden of disease among patients with prevalent Crohn's dis..:

Zhuleku, Evi ; Antolin-Fontes, Beatriz ; Borsi, Andras...
International Journal of Colorectal Disease. 38 (2023) 1 - p. , 2023

Link: https://doi.org/10.1007/..

2

Real-world outcomes associated with switching to anti-TNFsv..:

Zhuleku, Evi ; Antolin-Fontes, Beatriz ; Borsi, Andras...
Therapeutic Advances in Gastroenterology. 15 (2022) - p. 175628482211305 , 2022

Link: https://doi.org/10.1177/..

3

Treatment patterns, persistence with therapy, and outcomes ..:

Banon, Tamar ; Weil, Clara ; Borsi, Andras...
JGH Open. 6 (2022) 2 - p. 120-125 , 2022

Link: https://doi.org/10.1002/..

4

The cost burden of Crohn's disease and ulcerative colitis d..:

Alulis, Sarah ; Vadstrup, Kasper ; Olsen, Jens...
BMC Health Services Research. 21 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

5

A nationwide real-world study on dynamic ustekinumab dosing..:

Sipponen, Taina ; af Björkesten, Clas-Göran ; Hallinen, Taru...
Scandinavian Journal of Gastroenterology. 56 (2021) 6 - p. 661-670 , 2021

Link: https://doi.org/10.1080/..

6

Societal costs attributable to Crohn's disease and ulcerati..:

Vadstrup, Kasper ; Alulis, Sarah ; Borsi, Andras...
Scandinavian Journal of Gastroenterology. 55 (2020) 1 - p. 41-46 , 2020

Link: https://doi.org/10.1080/..

7

Objectively assessed disease activity and drug persistence ..:

af Björkesten, Clas-Göran ; Ilus, Tuire ; Hallinen, Taru...
European Journal of Gastroenterology & Hepatology. 32 (2020) 12 - p. 1507-1513 , 2020

Link: https://doi.org/10.1097/..

8

Anti-TNF dose escalation and drug sustainability in Crohn's..:

Kósa, Fruzsina ; Kunovszki, Péter ; Borsi, András...
Digestive and Liver Disease. 52 (2020) 3 - p. 274-280 , 2020

Link: https://doi.org/10.1016/..

9

Epidemiology, mortality and prevalence of colorectal cancer..:

Kunovszki, Péter ; Milassin, Ágnes ; Gimesi-Országh, Judit...
PLOS ONE. 15 (2020) 5 - p. e0233238 , 2020

Link: https://doi.org/10.1371/..

10

Treatment patterns for biologics in ulcerative colitis and ..:

Alulis, Sarah ; Vadstrup, Kasper ; Borsi, Andras...
Scandinavian Journal of Gastroenterology. 55 (2020) 3 - p. 265-271 , 2020

Link: https://doi.org/10.1080/..

11

Extraintestinal Manifestations and Other Comorbidities in U..:

Vadstrup, Kasper ; Alulis, Sarah ; Borsi, Andras...
Crohn's & Colitis 360. 2 (2020) 3 - p. , 2020

Link: https://doi.org/10.1093/..

12

Ustekinumab for Crohn's disease: a nationwide real-life coh..:

Eberl, Anja ; Hallinen, Taru ; af Björkesten, Clas-Göran...
Scandinavian Journal of Gastroenterology. 54 (2019) 6 - p. 718-725 , 2019

Link: https://doi.org/10.1080/..

13

Indirect costs associated with ulcerative colitis: a system..:

Constantin, Joelle ; Atanasov, Petar ; Wirth, Daniel.
BMC Gastroenterology. 19 (2019) 1 - p. , 2019

Link: https://doi.org/10.1186/..

14

Dose escalation and switching of biologics in ulcerative co..:

Gemayel, Nathalie C. ; Rizzello, Eugenio ; Atanasov, Petar..
Current Medical Research and Opinion. 35 (2019) 11 - p. 1911-1923 , 2019

Link: https://doi.org/10.1080/..

15

Sa1794 – Extra Intestinal Manifestations and Other Comorbid..:

Vadstrup, Kasper ; Alulis, Sarah ; Borsi, Andras...
Gastroenterology. 156 (2019) 6 - p. S-404-S-405 , 2019

Link: https://doi.org/10.1016/..